Alliance for Regenerative Medicine

Search ARM

We are the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society.

Learn More

Become a Member

Save the dates for the Cell and Gene Meeting on the Med!

The meeting, which runs from April 9-11, takes place in Rome, Italy. Early-bird registration deadline is January 5, 2024. Applications for company presentations are due December 15, 2023. Learn more!

Looking for updates on future ARM events? Sign up for our email list here!

Featured

Brief: Building Blocks and Platform Technologies for Cell and Gene Therapy Development

ARM and NIIMBL organized a scientific exchange on Building Blocks and Platform Technologies for Cell and Gene Therapy Development with the FDA. Our brief highlights the key takeaways of the workshop. A full white paper summary of the exchange will be published in early 2024.

READ THE BRIEF

Featured

Issue Brief: Medicaid Barriers to Accessing Cell & Gene Therapies

Highlighting the barriers that are precluding Medicaid beneficiaries’ access to innovative, life-changing cell and gene therapies.

READ THE BRIEF

Featured

Announcing the release of our Q2 2023 sector data

Looking to know what’s trending in the cell and gene therapy sector? Dive into our newly released Q2 2023 data report to view sector highlights in clinical trials, investment, and developer growth.

VIEW THE LATEST SECTOR DATA

Featured

Grow Internship Program applications are now open

Applications for ARM’s GROW Internship Program are now open. This program provides early-career opportunities for Black students in regenerative medicine.

LEARN MORE

Featured

Proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorized in the EU

Without changes recognizing the unique characteristics of ATMPs, the EU’s new Joint Clinical Assessment (JCA) will fail to deliver the next generation of transformative therapies to rare disease patients. ARM has issued a call to action to modernize the JCA methodology so it can deliver life-changing therapies to patients.

READ THE RELEASE

Learn About Regenerative Medicine

Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.

Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.

FIND OUT MORE

Discover the Alliance

ARM takes the lead on the most important issues facing the regenerative medicine and advanced therapy sector today:

Advocating for clear, predictable and harmonized regulatory and review pathways
Enabling market access and value-based reimbursement policies
Addressing industrialization and manufacturing hurdles
Conducting key stakeholder outreach, communication and education
Facilitating sustainable access to capital and identify sources of potential public funding.

Find Out More

Explore How ARM Leads the Way

As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.

FIND OUT MORE

Stay Connected

Newsletter Sign Up Twitter LinkedIn